Search | Clinical Trials Finder

Conditions: Acne Vulgaris
Interventions: Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan); Drug · Other
Lead sponsor: Seegpharm S.A.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 2,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 35
States / cities: Encino, California • Fullerton, California • La Mesa, California + 29 more

Conditions: External Anogenital Warts
Interventions: Podofilox Gel 0.5%, Condylox Topical Gel 0.5%, Placebo Gel; Drug
Lead sponsor: Dermax SA; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Osteoarthritis of the Knee
Interventions: OLT1177 Gel, Placebo gel; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: DeLand, Florida • South Miami, Florida • Raleigh, North Carolina

Conditions: Painful Diabetic Neuropathy
Interventions: Placebo Gel, Clonidine Topical Gel (ARC-4558); Drug
Lead sponsor: Arcion Therapeutics Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Sacramento, California • Santa Monica, California + 13 more

Conditions: Acne Vulgaris
Interventions: adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel); Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Fremont, California • Miami, Florida • Miramar, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Molluscum Contagiosum
Interventions: Benzoyl peroxide, Adapalene Gel; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 1 Year to 14 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Ocular Graft-versus-host Disease
Interventions: Pro-ocular™ topical gel, Placebo topical gel; Drug
Lead sponsor: Glia, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions: RGN-137, Placebo; Drug
Lead sponsor: Lenus Therapeutics, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more

Conditions: Acne Vulgaris, Acne
Interventions: CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Rosacea
Interventions: Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream; Drug · Other
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more

Conditions: Atopic Dermatitis
Interventions: DMT210 Topical Gel, Vehicle Control; Drug
Lead sponsor: Dermata Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Houston, Texas • Norfolk, Virginia

Conditions: Dermatitis, Atopic, Pruritus
Interventions: ASN008, ASN008 Matching Vehicle; Drug · Other
Lead sponsor: Formation Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 27
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more

Conditions: Lateral Canthal Lines
Interventions: Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel); Other · Drug
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 30 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%, CABTREO Topical Gel, Placebo Control; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Erythema, Rosacea
Interventions: CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 4
States / cities: Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more

Conditions: Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
Interventions: HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo; Drug
Lead sponsor: Hoth Therapeutics, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Irvine, California • Orange, California • Miami, Florida + 6 more

Conditions: Rosacea
Interventions: CD07805/47 gel, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Clinton Township, Michigan + 9 more

Conditions: BCCs in Gorlin Syndrome Patients
Interventions: PTX-022, Vehicle comparator; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 14
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Palo Alto, California + 11 more

Conditions: Actinic Keratosis
Interventions: PEP005 Topical Gel, Vehicle gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 25
States / cities: Hot Springs, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Ocular Graft-versus-host Disease
Interventions: Pro-ocular™ Topical Gel 1%, Placebo; Drug
Lead sponsor: Glia, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Acne Vulgaris
Interventions: Clindamycin 1% Gel, Placebo; Drug
Lead sponsor: Akorn, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more

Conditions: Non-segmental Vitiligo
Interventions: VYN201 Gel, Vehicle Gel; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more

Conditions: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, Topical Vehicle Gel; Drug
Lead sponsor: Pelage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more

Search by objective public record fields.

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

MC RCT - BPO vs Adapalene

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Safety and Efficacy of Pro-ocular™ 1% in Daily Scleral Lens Wearing Patients With Ocular Graft-versus-Host Disease

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA